Last reviewed · How we verify
NCT07512843
Acceptability and Efficacy of Group Reminiscence Intervention in a Sample of Patients With Schizophrenia
NA trial testing Group reminiscence therapy in Schizophrenia Cognition Autobiographical Memory Cognitive Remediation in 38 participants. Completed in 28 December 2025.
29 August 2025
Quick facts
| Lead sponsor | The Hashemite University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 February 2025 |
| Primary completion | 29 August 2025 |
| Estimated completion | 28 December 2025 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- Group reminiscence therapy
Conditions studied
- Schizophrenia Cognition Autobiographical Memory Cognitive Remediation — all drugs for Schizophrenia Cognition Autobiographical Memory Cognitive Remediation →
- SCHIZOPHRENIA 1 (Disorder) — all drugs for SCHIZOPHRENIA 1 (Disorder) →
- Hospitalized Adult Patients — all drugs for Hospitalized Adult Patients →
Sponsor
The Hashemite University
Who can join
Adults 18 to 64, any sex, with Schizophrenia Cognition Autobiographical Memory Cognitive Remediation or SCHIZOPHRENIA 1 (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aimed to test whether group reminiscence intervention for inpatients with schizophrenia is feasible, acceptable and preliminary effective. The effect of the intervention was evaluated on cognition, communication, and social function. Phase I was a multi-phase parallel study (n=38). The purpose of the study was to assess feasibility and preliminary efficacy by conducting an 8-week intervention with the participants. The study employed a single-group pretest-posttest evaluation. Phase II evaluated acceptability and performed a thematic analysis of semi-structured interviews conducted by a purposively selected subsample (N=8).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07512843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Hashemite University trials
Trials by the same sponsor.
- NCT07454200 — Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia · NA · not yet recruiting
- NCT07178288 — Assessment of Pressure Pain Threshold (PPT) and Conditioned Pain Modulation (CPM) After Effect in Patients With and With · NA · recruiting
- NCT06821022 — The Impact of Pain Neuroscience Education on Physical Therapy Student's Knowledge, Attitudes, Beliefs, and Behaviours To · NA · completed
- NCT05987228 — Effects of Orally Administered Thymus Vulgaris Leaves on Memory, Anxiety, Depression, and Sleep Quality in University St · NA · completed
- NCT05999071 — Coriandrum Sativum Seeds Improve Memory, Alleviate Anxiety and Depression, and Enhance Sleep Quality in University Stude · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07512843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hashemite University
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07512843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing